Chief Financial Officer

Nuvalent reports Q3 EPS ($1.70), consensus ($1.32)

Nuvalent Highlights Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2025 Financial Results

Nuvalent price target raised by $16 at Piper Sandler, here's why

Nuvalent presents preliminary data for neladalkib from ALKOVE-1 Phase 1/2 trial

Manager, Regulatory Advertising & Promotion Submissions

Nuvalent is an early-stage company focused on developing selective medicines for cancer patients. The Manager, Regulatory Advertising & Promotion Submissions will oversee the compliant preparation, review, and submission of promotional materials to the Office of Prescription Drug Promotion, ensuring adherence to regulatory requirements.

Sign up with Google

Sign in with Google